CytoDyn to Present at the AACR Annual Meeting 2026
Download as PDFApril 14, 2026 8:30am EDT
VANCOUVER, Wash., April 14, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”), today announced that it will be presenting two posters at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California.
Details of the poster presentations are as follows:
Abstract title:
Leronlimab induces PD-L1 expression and is associated with long term survival with an ICI in PD-L1 low metastatic TNBC
Presenter: Richard Pestell, M.D., Ph.D., FRCP AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn
Date and Time: April 19, 2026, from 2:00 p.m. – 5:00 p.m. PST.
Poster ID: 1033
Location:
Section 41, Board 1
Abstract title:
Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer
Presenter: Pashtoon M. Kasi, M.D., M.S., Medical Director at City of Hope
Date and Time: April 21, 2026, from 2:00 p.m. – 5:00 p.m. PST.
Poster ID: 6466
Location:
Section 41, Board 14
“We are encouraged by the continued progress being made as we advance leronlimab and explore its potential applications across solid tumors,” said Jacob Lalezari, M.D., CEO of CytoDyn. “The research being presented at AACR reflects the growing body of scientific work examining CCR5 biology and its role in the tumor microenvironment. Together, these studies help deepen our understanding of how leronlimab may enhance immune responses and inform our broader strategy to develop new treatment approaches for patients with difficult-to-treat cancers.”
A copy of the presentations will be made available on CytoDyn’s website under the Publications & Posters section after it is presented at the symposium.
Download as PDFApril 14, 2026 8:30am EDT
VANCOUVER, Wash., April 14, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”), today announced that it will be presenting two posters at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California. Details of the poster presentations are as follows:
Abstract title:
Leronlimab induces PD-L1 expression and is associated with long term survival with an ICI in PD-L1 low metastatic TNBC
Presenter: Richard Pestell, M.D., Ph.D., FRCP AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn
Date and Time: April 19, 2026, from 2:00 p.m. – 5:00 p.m. PST.
Poster ID: 1033
Location:
Section 41, Board 1
Abstract title:
Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer
Presenter: Pashtoon M. Kasi, M.D., M.S., Medical Director at City of Hope
Date and Time: April 21, 2026, from 2:00 p.m. – 5:00 p.m. PST.
Poster ID: 6466
Location:
Section 41, Board 14
“We are encouraged by the continued progress being made as we advance leronlimab and explore its potential applications across solid tumors,” said Jacob Lalezari, M.D., CEO of CytoDyn. “The research being presented at AACR reflects the growing body of scientific work examining CCR5 biology and its role in the tumor microenvironment. Together, these studies help deepen our understanding of how leronlimab may enhance immune responses and inform our broader strategy to develop new treatment approaches for patients with difficult-to-treat cancers.”
A copy of the presentations will be made available on CytoDyn’s website under the Publications & Posters section after it is presented at the symposium.
9
